Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect

Gene Therapy
K-J ChoiC-O Yun

Abstract

Oncolytic adenoviral vectors are currently being developed as biologic anticancer agents. Coupling the lytic function of an oncolytic adenovirus (Ad) with its ability as a transgene delivery system represents a powerful extension of this methodology. A clear advantage is the amplification of a therapeutic gene, as replicating vectors would be able to infect and deliver the gene of interest to neighboring cells. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of the most potent stimulators of a specific and long-lasting antitumor immunity and its important role in the maturation of antigen-presenting cells to induce T-cell activation has been well documented. Similarly, the B7 family has also been shown to play an integral role in mediating an antitumor response. Most tumor cells, however, lack the expression of these costimulatory molecules on their surface, thus escaping immune system recognition. To increase the antitumor effect of an oncolytic Ad, we have generated an E1B 55 kDa-deleted oncolytic adenoviral vector, YKL-GB, that expresses both GM-CSF and B7-1. The therapeutic efficacy of YKL-GB Ad was evaluated in immunocompetent mice bearing murine melanoma B16-F10 tumors. Significant inhibition of tumor gro...Continue Reading

References

Jan 1, 1991·Annual Review of Immunology·R M Steinman
Jan 1, 1995·Advances in Experimental Medicine and Biology·F GranucciP Ricciardi-Castagnoli
Jan 1, 1996·Immunologic Research·T A JudgeL A Turka
Feb 1, 1997·Current Opinion in Immunology·M CellaA Lanzavecchia
Oct 18, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·D HaddadW R Weiss
Oct 31, 2000·International Journal of Cancer. Journal International Du Cancer·H LeeJ H Kim
Jun 7, 2002·The Journal of Clinical Endocrinology and Metabolism·Giuseppe PortellaAlfredo Fusco
Aug 21, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Tara M C HornellElizabeth D Mellins
Sep 5, 2003·Cancer Immunology, Immunotherapy : CII·Ping-Ying PanShu-Hsia Chen

❮ Previous
Next ❯

Citations

Nov 6, 2010·Cell Death and Differentiation·C T CheungR Wadhwa
Feb 7, 2009·Cancer Gene Therapy·J J Cody, J T Douglas
Apr 10, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Yoon-A KangChae-Ok Yun
Sep 10, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jing-Hua HuangChae-Ok Yun
Dec 24, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Kathryn Ottolino-PerryJ Andrea McCart
Aug 12, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Engin GürlevikStefan Kubicka
Jun 17, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Byram W BridleYonghong Wan
Apr 7, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Song-Nan ZhangChae-Ok Yun
Aug 9, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Otto HemminkiAkseli Hemminki
Jan 20, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ji Young YooChae-Ok Yun
Jan 18, 2012·Human Gene Therapy·Taeyoung KooChae-Ok Yun
Nov 6, 2013·Immunotherapy·Matthew J Atherton, Brian D Lichty
Mar 4, 2014·Human Gene Therapy·Dragomira MajhenJerome Custers
Jun 28, 2014·Journal for Immunotherapy of Cancer·Howard L KaufmanCraig L Slingluff
Oct 16, 2013·Expert Review of Vaccines·Noura B Elsedawy, Stephen J Russell
Nov 9, 2014·Expert Opinion on Pharmacotherapy·Sarah SlootJonathan S Zager
Aug 6, 2010·Expert Opinion on Biological Therapy·Dong-Sheng PeiJun-Nian Zheng
Apr 21, 2010·Expert Opinion on Biological Therapy·Dong-Sheng Pei, Jun-Nian Zheng
Feb 11, 2016·Immunotherapy·Linda HammerichJoshua D Brody
Oct 27, 2010·The British Journal of Dermatology·M HochbergA Panet
Dec 13, 2012·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·Won Jai LeeChae-Ok Yun
Jan 4, 2012·Advanced Drug Delivery Reviews·Joung-Woo ChoiChae-Ok Yun
Jun 28, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Oh-Joon KwonChae-Ok Yun
Dec 4, 2015·Molecular Oncology·Linda HammerichJoshua D Brody
Apr 9, 2016·Oncoimmunology·Jonathan PolLorenzo Galluzzi
Oct 11, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Joung-Woo ChoiSung Wan Kim
May 7, 2015·International Journal of Cancer. Journal International Du Cancer·Il-Kyu ChoiChae-Ok Yun
Dec 31, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jaesung KimSung Wan Kim
Jul 31, 2013·Oncoimmunology·Erika VacchelliLorenzo Galluzzi
Dec 18, 2012·Oncoimmunology·José I QuetglasCristian Smerdou
Aug 7, 2014·Oncoimmunology·Jonathan PolLorenzo Galluzzi
May 18, 2010·Integrative Biology : Quantitative Biosciences From Nano to Macro·Carlos L ReisDavid Dingli
Oct 27, 2012·Journal of Perinatology : Official Journal of the California Perinatal Association·H SteinD B White
Jul 6, 2014·Nature Reviews. Cancer·Brian D LichtyJohn C Bell
May 27, 2008·International Journal of Cancer. Journal International Du Cancer·Qi-Xiang LiFlossie Wong-Staal

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.